Enhancing endothelial progenitor cell for clinical use

Ye, Lei; Poh, Kian‐Keong

doi:10.4252/wjsc.v7.i6.894

Cited by 17 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the endothelial differentiation potential can vary according to local environmental conditions and change over time. For these reasons, as long as clinical applications are concerned, a detailed functional characterization of these cells may be even more relevant compared with their antigenic phenotype (65)(66)(67).…”

Section: Discussionmentioning

confidence: 99%

Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation

Danova

Comolli

Manzoni

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Malignant tumors are characterized by uncontrolled cell growth and metastatic spread, with a pivotal importance of the phenomenon of angiogenesis. For this reason, research has focused on the development of agents targeting the vascular component of the tumor microenvironment and regulating the angiogenic switch. As a result, the therapeutic inhibition of angiogenesis has become an important component of anticancer treatment, however, its utility is partly limited by the lack of an established methodology to assess its efficacy in vivo. Circulating endothelial cells (CECs), which are rare in healthy subjects and significantly increased in different tumor types, represent a promising tool for monitoring the tumor clinical outcome and the treatment response. A cell population circulating into the blood also able to form endothelial colonies in vitro and to promote vasculogenesis is represented by endothelial progenitor cells (EPCs). The number of both of these cell types is extremely low and they cannot be identified using a single marker, therefore, in absence of a definite consensus on their phenotype, require discrimination using combinations of antigens. Multiparameter flow cytometry (FCM) is ideal for rapid processing of high numbers of cells per second and is commonly utilized to quantify CECs and EPCs, however, remains technically challenging since there is as yet no standardized protocol for the identification and enumeration of these rare events. Methodology in studies on CECs and/or EPCs as clinical biomarkers in oncology is heterogeneous and data have been obtained from different studies leading to conflicting conclusions. The present review presented a critical review of the issues that limit the comparability of results of the most significant studies employing FCM for CEC and/or EPC detection in patients with cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation

Danova

Comolli

Manzoni

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Consequently, a simple measurement of circulating EPC number showing potential for improved endothelial function based on labeling of specific antigens might be wrong step to determine the regenerative ability of EPCs. Probably, we have precious many investigations with controversial results regarding predictive role of EPC count in peripheral blood in CV disease and diabetes [36][37][38][39][40][41]. However, lack of accessible and affordable approved methods regarding an assay of ability to survive, moving, differentiation, and colony forming of preconditioned EPCs is challenge for use of this approach in routine clinical practice, although there are data that the even simple measurement of EPCs in circulation might be useful for CV risk predicting in patients with acute coronary syndrome, atherosclerosis, heart failure and diabetes [42,43].…”

Section: Discussionmentioning

confidence: 99%

Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?

Berezin¹

2017

Insights in Biomed

View full text Add to dashboard Cite

“…EPCs as a candidate cell source for therapy offer many attractive characteristics, including (a) ready accessibility from peripheral blood; (b) potent angiogenic and vasculogenic effects; and (c) the stability of the lineage and a reduced risk of tumorigenicity. These features led to many studies on their possible utility for therapeutic neovascularization, for which hematopoietic EPCs have been largely favored in such applications because of their ease of harvest, with minimal manipulations and culture periods [31].…”

Section: Clinical Application Of Epcs In Regenerative Medicinementioning

confidence: 99%

Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges

Chong

Chan

2016

Stem Cells Translational Medicine

174

145

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) are currently being studied as candidate cell sources for revascularization strategies. Significant advances have been made in understanding the biology of EPCs, and preclinical studies have demonstrated the vasculogenic, angiogenic, and beneficial paracrine effects of transplanted EPCs in the treatment of ischemic diseases. Despite these promising results, widespread clinical acceptance of EPCs for clinical therapies remains hampered by several challenges. The present study provides a concise summary of the different EPC populations being studied for ischemic therapies and their known roles in the healing of ischemic tissues. The challenges and issues surrounding the use of EPCs and the current strategies being developed to improve the harvest efficiency and functionality of EPCs for application in regenerative medicine are discussed. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:530-538 SIGNIFICANCEEndothelial progenitor cells (EPCs) have immense clinical value for cardiovascular therapies. The present study provides a concise description of the EPC subpopulations being evaluated for clinical applications. The current major lines of investigation involving preclinical and clinical evaluations of EPCs are discussed, and significant gaps limiting the translation of EPCs are highlighted. The present report could be useful for clinicians and clinical researchers with interests in ischemic therapy and for basic scientists working in the related fields of tissue engineering and regenerative medicine.

show abstract

Enhancing endothelial progenitor cell for clinical use

Cited by 17 publications

References 49 publications

Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation

Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation

Preconditioned Endothelial Progenitor Cells as Biomarker of Vascular Reparation?

Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges

Contact Info

Product

Resources

About